SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime ...
(RTTNews) - Windtree Therapeutics, Inc. (WINT), a clinical-stage biotechnology company focused on advancing therapies for critical care conditions, announced it is targeting July 2025 for the interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results